Strategic Partnerships Opportunity to expand co-development and companion diagnostic projects with pharma partners (e.g., ongoing BMS collaborations) by offering MTAP and MTAP deletion CDx capabilities to support targeted therapies and broaden real-world data applications.

Next-Gen Diagnostics Highlight FoundationOne CDx expansion efforts as a pathway to deeper market penetration in NGS-based companion diagnostics, emphasizing MTAP deletion detection and broader tumor profiling to align with oncology partners seeking precision medicine solutions.

Clinical Evidence Leverage ongoing real-world data and AI-enabled insights to demonstrate improved patient outcomes and faster treatment decisions, positioning FMI as the data-driven cornerstone for payer discussions and value-based contracting.

Leadership Transition Recent leadership changes present an opening to engage during transition periods with strategic messaging on continuity, investment in innovation, and ramped collaborations to accelerate product adoption and expansion plans.

Global Expansion Capitalize on Roche affiliation and international reach to pursue cross-border trials and market access opportunities, offering integrated diagnostic and genomic data services to pharmaceutical and biotechnology customers worldwide.